Adverse event: 1b. Death ‐ suicide ‐ by long term · people with severe mental disorders
Intensive Case Management showed no clear difference in adverse event: 1b. Death ‐ suicide ‐ by long term compared with standard care (low certainty).
1 finding from 1 review
Relapse · people with severe mental disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · people with severe mental disorders
Intensive Case Management may leads to lower global state: 1. Leaving the study early ‐ by long term compared with standard care (low certainty).
1 finding from 1 review
Social functioning: 2. Employment status (various measurements) ‐ by long term ‐ not employed at the end of the trial · people with severe mental disorders
It is very uncertain whether intensive Case Management changes social functioning: 2. Employment status (various measurements) ‐ by… compared with standard care (very low certainty).
1 finding from 1 review
Mental state: No clinically important improvement · people with severe mental disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use: 1. Average number of days in hospital per month ‐ by about 24 months · people with severe mental disorders
1 finding from 1 review
Service use: 3b. Average number of admissions (skewed data ‐ sample size ≧ 200) ‐ by long term · people with severe mental disorders
1 finding from 1 review
Adverse event: 1b. Death ‐ suicide ‐ by long term · people with severe mental disorders
Intensive Case Management showed no clear difference in adverse event: 1b. Death ‐ suicide ‐ by long term compared with non‐Intensive Case Management (low certainty).
1 finding from 1 review
Clinical response: No clinically important response ‐ as defined by each of the studies · schizophrenia or related disorders
It is very uncertain whether combinations of antipsychotic drugs changes clinical response: No clinically important response ‐ as defined by… compared with single antipsychotic drugs (very low certainty).
1 finding from 1 review
Relapse · schizophrenia or related disorders
1 finding from 1 review
Leaving the study early · schizophrenia or related disorders
Combinations of antipsychotic drugs showed no clear difference in leaving the study early compared with single antipsychotic drugs (low certainty).
1 finding from 1 review
Hospital admissions · schizophrenia or related disorders
It is very uncertain whether combinations of antipsychotic drugs changes service utilisation: Hospital admission compared with single antipsychotic drugs (very low certainty).
1 finding from 1 review
Service utilisation: Change in hospital status ‐ not reported · schizophrenia or related disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: Serious event or requiring discontinuation · schizophrenia or related disorders
It is very uncertain whether combinations of antipsychotic drugs changes adverse events: Serious event or requiring discontinuation compared with single antipsychotic drugs (very low certainty).
1 finding from 1 review
Quality of life · schizophrenia or related disorders
1 finding from 1 review
Tranquilisation or asleep not asleep at 2 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep not asleep at 2 hours compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Global outcome ‐ need for benzodiazepine during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcomes: need for benzodiazepine 2 compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome: general ‐ no improvement · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: general ‐ no overall improvement compared with COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE (very low certainty).
1 finding from 1 review
Adverse effect: any serious, specific ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found